👩⚕️💉Danish pharmaceutical company Novo Nordisk’s anti-obesity drug Wegovy may have more benefits than just helping people lose weight.
📄 According to a study published in The Journal of the American College of Cardiology, people who took this drug during the pandemic were 33% less likely to die from COVID-19.
📉 In addition, the semaglutide injection also reduced the overall mortality rate by 19%.
🩺 Although people taking Wegovy became infected with COVID-19 at the same rate as those taking a placebo, their risk of dying from the infection was significantly reduced.
💼 This protective effect was observed immediately, even before participants lost a significant amount of weight.
🥼In addition, the drug also reduced the mortality rate from all causes, suggesting that treating obesity may improve the life expectancy of people with the condition.
🏥Do you think more benefits could be discovered from this drug?
Fuente: The New York Times
#Obesity #Covid #Health #Treatment #Wegovy #Study
